Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
AMSELEM, L. et al. Intravitreal injection of Bevacizumab (Avastin®) for retinal angiomatous proliferation. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.1, pp.53-55. ISSN 0365-6691.
Clinical case: An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epithelium detachment. Three months after the injection, no ocular complications were observed, VA was 20/20 and the OCT showed an almost normal macular contour. Discussion: Intravitreal injection of bevacizumab may provide another treatment option for patients with RAP.
Palabras clave : Bevacizumab; intravitreal injection; retinal angiomatous proliferation; age-related macular degeneration; optical coherence tomography.